EGFR and neoplasm: Data from the CRYSTAL and TAILOR studies also confirm that adding cetuximab to chemotherapy improved the survival benefit of first-line treatment for patients with RAS wt mCRC, irrespective of tumor EGFR status (Fig. 6a-c).